Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to
maintain standard imatinib dose. Skin rash is a relatively common and sometimes severe
adverse event of imatinib in GIST patients and may affect imatinib compliance. Our previous
retrospective study suggested that severe skin rash induced by imatinib can be managed by
systemic steroid without imatinib dose interruption or reduction. This phase II study was
conducted to evaluate the efficacy and safety of systemic steroid in GIST patients with
imatinib-associated severe skin rash.